The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: PageGroup Slumps After Profit Warning

Wed, 10th Jul 2019 10:40

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - LOSERS----------Micro Focus International, down 6.5%. Shares in the software company continued to slide after it reported a drop in revenue and maintained its annual guidance on Tuesday. Micro Focus on Tuesday also said its high-profile acquisition of Hewlett Packard's software business was still proving difficult to integrate into its existing operations, stressing it was a "complex and significant progamme of work". The stock is down 10% since the start of the week. ----------Ashtead Group, down 1.0%. Morgan Stanley cut the equipment rentals firm to Equal Weight from Overweight. ----------FTSE 250 - WINNERS----------JD Wetherspoon, up 3.2%. The pub chain said sales were higher in the year so far and its expectations for its current financial year are unchanged. Wetherspoon said its like-for-like sale were up 6.9% for the ten weeks to July 7, with total sales up 6.6% for the same period. Year-to-date, like-for-like sales were up 6.7% while total sales rose 7.4%. The company's financial year ends on July 28, on which date the company expects to have net debt of around GBP745 million. Since its financial year began, JD Wetherspoon has opened five new pubs and disposed of another nine, with no more openings planned for its current financial year. Chair Tim Martin said that "the company's expectation for our annual results is unchanged for the current financial year".----------Playtech, up 3.0%. JPMorgan started coverage on the gambling software provider with an Overweight rating. ----------FTSE 250 - LOSERS----------PageGroup, down 15%. The recruiter said it achieved gross profit growth in its first half but expects an annual operating profit at the lower end of market expectations due to "challenging" macroeconomic conditions. Page said total gross profit for the first half of 2019 was GBP433.5 million, a 9.5% increase as reported and also 9.5% at constant currency. For the second quarter alone, gross profit was GBP224.6 million, a 7.9% rise over its GBP208.2 million gross profit the year before and a 7.4% rise at constant currency. In both the second half and the second quarter, gross profit increased most sharply in the Americas, with reported growth of 21% to GBP69.1 million from GBP57.3 million in the first half and 19% to GBP36.9 million from GBP30.9 million in the second quarter. Europe, the Middle East & Africa - which accounted for 49% of the group's profit in the first half and 48% in the second quarter - also performed well with half-year reported profit growth of 9.3% to GBP213.1 million from GBP194.9 million. Despite this growth, 2019 operating profit is expected to be at the low end of market expectations due to a difficult economic environment, Page said. ----------Hays, down 6.0%. UBS cut the recruiter to Neutral from Buy, and it also suffered a read-across from PageGroup. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Redx Pharma. Shares in the cancer and fibrosis drug discovery company doubled to 14 pence after it signed a definitive agreement with Nasdaq-listed Jazz Pharmaceuticals to sell its pan-RAF inhibitor programme. As part of the agreement, Redx will receive an upfront payment of USD3.5 million in cash but is eligible to receive up to USD203 million in development, regulatory and commercial milestone payments. The next milestone is the initiation of investigational new drug studies, followed by an IND submission to the US Food & Drug Administration. Redx also is eligible for incremental tiered royalties in "mid-single digit" percentage, based on any future net sales. ----------Xeros Technology, up 32%. The water saving and effluent reduction technology firm said its patent application for microfibre filters in domestic washing machines has been published. The patent application for the device, trademarked XFiltra, can now be licenced by domestic washing machine manufacturers. The application was published by the World Intellectual Property Organization. Xeros noted that the washing of clothes made from synthetic fibres is "the single biggest source of primary microplastics released into the oceans every year", with up to 700,000 microfibres released into the environment in just one domestic wash cycle.----------OTHER MAIN MARKET AND AIM - LOSERS----------Superdry, down 0.5%. The troubled fashion retailer reduced its annual payout after reporting a swing to loss in its most recently ended financial year. The company chopped its final dividend to 2.2 pence a share from 21.3p last year, taking the full-year payout to 11.5p per share, little more than a third the 31.2p paid in its financial 2018. Superdry said its revenue for the 52 weeks to April 27 was GBP871.7 million, broadly flat compared to GBP872.0 million reported for the same period a year ago, due to "a difficult retail climate". Superdry explained that its first half performance benefited from discounting and space growth, but it saw poor performance in the second half across all channels. The company posted a loss of GBP85.4 million, compared to GBP65.3 million profit reported a year earlier, as its underlying operating margin declined by 600 basis points to 5.5% from 11.5% the year before. Despite its struggles, Jefferies started coverage on Superdry with a Buy rating.----------

More News
13 Dec 2022 15:53

UK earnings, trading statements calendar - next 7 days

Wednesday 14 December 
Cohort PLCHalf Year Results
CyanConnode Holdings PLCHalf Year Results
Foresight Sustainable Forestry Co PLCFull Year Results
IntegraFin Holdings PLCFull Year Results
SThree PLCTrading Statement
Tui AGFull Year Results
Watches of Switzerland Group PLCHalf Year Results
Thursday 15 December 
Biffa PLCHalf Year Results
C4X Discovery Holdings PLCFull Year Results
Currys PLCHalf Year Results
Libertine Holdings PLCHalf Year Results
RWS Holdings PLCFull Year Results
Serco Group PLCTrading Statement
Friday 16 December 
Gore Street Energy Storage Fund PLCHalf Year Results
Hollywood Bowl Group PLCFull Year Results
Monday 19 December 
Thruvision Group PLCHalf Year Results
Tuesday 20 December 
Jersey Electricity PLCFull Year Results
Petrofac LtdTrading Statement
Redx Pharma PLCFull Year Results
  
Copyright 2022 Alliance News Ltd. All Rights Reserved.

Read more
11 Nov 2022 15:24

TRADING UPDATES: De La Rue defends chair; Resolute Mining fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
11 Oct 2022 14:51

TRADING UPDATES: Scirocco repays loan; Vp says rail strikes slow works

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Oct 2022 22:06

TRADING UPDATES: Blencowe Resources sees potential interest from China

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Aug 2022 13:58

Redx Pharma staff sell 1.5 million shares via accelerated bookbuild

(Alliance News) - Redx Pharma PLC on Friday confirmed that Chief Scientific Officer Richard Armer and other current and former employees have sold a total of 1.5 million shares at 59 pence each via an accelerated bookbuild.

Read more
3 Aug 2022 17:57

IN BRIEF: Redx Pharma employees to sell at least GBP605,120 in shares

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Chief Scientific Officer Richard Armer and other current and former employees look to sell 1.5 million shares at a minimum price of 59 pence each via an accelerated bookbuild, which is 11% discount to Tuesday's closing price of 66.50p.

Read more
27 Jun 2022 16:01

IN BRIEF: Redx Pharma reports "encouraging" fibrosis treatment data

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes encouraging preclinical data for the potential of its Porcupine and ROCK inhibitors to tackle cancer-associated fibrosis. Further data supported the ROCK inhibitor as a potential treatment for fibrostenotic Crohn's disease.

Read more
23 Jun 2022 11:29

IN BRIEF: Redx Pharma narrows half-year loss as pipeline progresses

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - In the half year ended March 31, pretax loss narrows to GBP9.7 million from GBP12.7 million year-on-year. Revenue multiplies to GBP8.4 million from GBP2.1million. Reports strong progress across its pipeline, especially its lead oncology asset RXC004 moving into phase II clinical trials, and its lead fibrosis asset, RXC007, reporting "encouraging" phase I safety data. Says its Rock inhibitor RXC008 has the potential to become a first-in-class treatment for fibrostenotic Crohn's disease, and is likely to be ready to enter the clinic by the end of next year.

Read more
16 Jun 2022 16:05

UK earnings, trading statements calendar - next 7 days

Friday 17 June 
Tesco PLCQ1 Results
Monday 20 June 
Associated British Foods PLCQ3 Results
SysGroup PLCFull Year Results
SThree PLCTrading Statement
Tuesday 21 June 
DS Smith PLCFull Year Results
Gear4Music PLCFull Year Results
Monks Investment Trust PLCFull Year Results
Record PLCFull Year Results
Safestore Holdings PLCHalf Year Results
Telecom Plus PLCFull Year Results
Wednesday 22 June 
Berkeley Group Holdings PLCFull Year Results
Liontrust Asset Management PLCFull Year Results
Micro Focus International PLCHalf Year Results
Thursday 23 June 
DeepVerge PLCFull Year Results
First Property Group PLCFull Year Results
Manolete Partners PLCFull Year Results
Naked Wines PLCFull Year Results
Oxford Metrics PLCHalf Year Results
Redx Pharma PLCHalf Year Results
Serco Group PLCTrading Statement
Volex PLCFull Year Results
XPS Pensions Group PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
15 Jun 2022 10:24

Redx Pharma rises on FDA clearance for solid tumour treatment JZP815

(Alliance News) - Redx Pharma PLC on Wednesday said the US Food & Drug Administration has cleared the investigational new drug application for JZP815, a pan-RAF inhibitor for the treatment of solid tumours and haematological malignancies.

Read more
19 May 2022 18:55

TRADING UPDATES: Knights tips revenue hike; Gym Group eyes growth

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 May 2022 19:37

IN BRIEF: Redx Pharma to raise GBP30 million to fund pipelines

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Proposes to raise GBP30 million through a placing to institutional investors of shares at a price of 59 pence each.

Read more
8 Apr 2022 19:41

IN BRIEF: Redx Pharma notes "encouraging" RXC004 data in cancer

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes "encouraging" preclincal data for RXC004 as a targeted therapy for Wnt-ligand driven cancer.

Read more
5 Apr 2022 21:39

TRADING UPDATES: Alpha FX restarts relationship; Atalaya resources up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 11:05

IN BRIEF: Redx Pharma to start new Crohn's disease study in late 2023

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Announces end of 2023 as start of phase 1 studies for its Crohn's disease clinical development candidate RXC008. The inhibitor is designed to act exclusively in the gastrointestinal tract at the site of fibrosis in Crohn's disease patients. Up to 50% of patients with Crohn's disease can develop significant fibrosis, the company says, citing a 2013 study published by the National Center for Biotechnology Information based in Bethesda, Maryland, United States.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.